EGFR和ALK靶向治疗及其耐药机制的研究进展(5)
[21] Wakelee HA，Soria JC，Sequist LV，et al. First-in-human evaluation of CO-1686，an irreversible，highly selective tyrosine kinase inhibitor of mutations of EGFR(activating and T790M)[J]. Thorac Oncol，2013，34(5)：203-220.
[22] Wakelee HA，Soria JC，Sequist LV，et al. First-in-human evaluation of CO-1686，an irreversible，highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)[J]. Thorac Oncol，2013，34(5)：203-220.
[23] Wu YL，Yang JCH，Kim DW，et al. Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut)，MET-positive NSCLC：A single-arm phase lb/ll study [J]. ASCO Meeting Abstracts，2014， 32(8)：8017-8020.
[24] Friboulet L，Li N，Katayama R，et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer [J]. Cancer Discov，2014，4(8)：662-673.
[25] Shaw AT，Kim DW，Mehra R，et al. Ceritinib in ALK-rearranged non-small-cell lung cancer [J]. N Engl J Med，2014，370(4)：1189-1197.
[26] Neckers L，Workman P. Hsp90 molecular chaperone inhibitors： are we there yet？[J]. Clin Cancer Res，2012，18(4)：64-76.
[27] Normant E，Paez G，West KA，et al. The HSP90 Inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models [J]. Oncogene，2011，30(5)：2581-2586.
(收稿日期：2016-02-22 本文编辑：程 铭) (李楠 叶明翔 张勇 曹晶 张信信 )
[22] Wakelee HA，Soria JC，Sequist LV，et al. First-in-human evaluation of CO-1686，an irreversible，highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)[J]. Thorac Oncol，2013，34(5)：203-220.
[23] Wu YL，Yang JCH，Kim DW，et al. Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut)，MET-positive NSCLC：A single-arm phase lb/ll study [J]. ASCO Meeting Abstracts，2014， 32(8)：8017-8020.
[24] Friboulet L，Li N，Katayama R，et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer [J]. Cancer Discov，2014，4(8)：662-673.
[25] Shaw AT，Kim DW，Mehra R，et al. Ceritinib in ALK-rearranged non-small-cell lung cancer [J]. N Engl J Med，2014，370(4)：1189-1197.
[26] Neckers L，Workman P. Hsp90 molecular chaperone inhibitors： are we there yet？[J]. Clin Cancer Res，2012，18(4)：64-76.
[27] Normant E，Paez G，West KA，et al. The HSP90 Inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models [J]. Oncogene，2011，30(5)：2581-2586.
(收稿日期：2016-02-22 本文编辑：程 铭) (李楠 叶明翔 张勇 曹晶 张信信 )